Search clinical trials for: Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant

Total 9 results

GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults

Herpes Simplex
GlaxoSmithKline

Completed

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Herpes Simplex
GlaxoSmithKline

Completed

Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

Herpes Simplex

United States, Belgium, Canada
GlaxoSmithKline

Completed

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

Prophylaxis for Herpes Simplex

Austria, Germany, Belgium, United States, Australia, Canada, Denmark, France, Puerto Rico, South Africa, Spain, Switzerland
GlaxoSmithKline

Completed

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Herpes Simplex

United States, Australia, Spain, Romania, United Kingdom, Belgium, Canada, Estonia, France, Hungary, New Zealand, Sweden, Netherlands, Norway, Greece, Denmark, Iceland, Lithuania
GlaxoSmithKline

Completed

HerpeVac Trial for Young Women

Herpes Simplex Infection

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma In Situ

United States

3

Subscribe